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Whether second generatation DES stents are better than the first is not clear. Most trials compare new type of stents with paclitaxel eluting stents. 
Limited data are available on the direct comparison of new stents versus sirolimus eluting stents (SES).
The APPENDIXAMI is a large randomized, prospective single-centre study to assess the efficacy of the everolimus eluting stent (EES, XienceV) 
compared to SES (Cypher) in all comers. Endpoint of study is one year death, MI, PCI and/or CABG. Data are analysed by an independent statistician.
From 2007 900 patients are included, age is 64±13yrs. ACS was indication for PCI in 16% of the procedures. Diabetes is present in 17%, smoking in 
26%, hypertension in 44% and renal failure in 12% of the patients, respectively. Type C lesions were present in 21% of the patients. In 10% restenotic 
lesions were treated. In 99% SES could be placed versus 100% in EES. Interim analysis showed no difference in one year outcome (see figure, P=ns)
Conclusion: Our trial is one of the few comparing EES with SES prospectively. It may show that both stents perform equally.
